<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[RSS Feed]]></title><description><![CDATA[RSS Feed]]></description><link>http://direct.ecency.com</link><image><url>http://direct.ecency.com/logo512.png</url><title>RSS Feed</title><link>http://direct.ecency.com</link></image><generator>RSS for Node</generator><lastBuildDate>Wed, 15 Apr 2026 07:23:34 GMT</lastBuildDate><atom:link href="http://direct.ecency.com/@gut50/rss" rel="self" type="application/rss+xml"/><item><title><![CDATA[Febuxostat (Uloric) and its problem with cardiovascular mortality]]></title><description><![CDATA[Despite drug safety problems of cardiovascular mortality with Febuxostat (Uloric), the benefits might still be seen to outweigh risks for selected gout patients. This notion may become more and more disputed,]]></description><link>http://direct.ecency.com/theragenomics/@gut50/febuxostat-uloric-and-its-problem-with-cardiovascular-mortality</link><guid isPermaLink="true">http://direct.ecency.com/theragenomics/@gut50/febuxostat-uloric-and-its-problem-with-cardiovascular-mortality</guid><category><![CDATA[theragenomics]]></category><dc:creator><![CDATA[gut50]]></dc:creator><pubDate>Thu, 16 May 2019 14:49:06 GMT</pubDate></item><item><title><![CDATA[Grossesse et risques de malformations: Il n'y a pas seulement le valproate]]></title><description><![CDATA[may 01, 2019 - En France, l’Agence nationale de sécurité du médicament et des produits de santé (ANSM) viens de publier une analyse des données disponibles sur le risque de malformations et de troubles]]></description><link>http://direct.ecency.com/theragenomics/@gut50/grossesse-et-risques-de-malformations-il-n-y-a-pas-seulement-le-valproate</link><guid isPermaLink="true">http://direct.ecency.com/theragenomics/@gut50/grossesse-et-risques-de-malformations-il-n-y-a-pas-seulement-le-valproate</guid><category><![CDATA[theragenomics]]></category><dc:creator><![CDATA[gut50]]></dc:creator><pubDate>Sat, 04 May 2019 07:15:57 GMT</pubDate></item><item><title><![CDATA[Lemtrada: Deleterious unwanted effects in some multiple sclerosis patients]]></title><description><![CDATA[Lemtrada: Deleterious unwanted effects in some multiple sclerosis patients Alemtuzumab (Lemtrada) is used in the treatment of multiple sclerosis (MS). Moreover, Alemtuzumab, under the Tradenames of Campt,]]></description><link>http://direct.ecency.com/theragenomics/@gut50/lemtrada-deleterious-unwanted-effects-in-some-multiple-sclerosis-patients</link><guid isPermaLink="true">http://direct.ecency.com/theragenomics/@gut50/lemtrada-deleterious-unwanted-effects-in-some-multiple-sclerosis-patients</guid><category><![CDATA[theragenomics]]></category><dc:creator><![CDATA[gut50]]></dc:creator><pubDate>Thu, 02 May 2019 04:55:12 GMT</pubDate></item></channel></rss>